Largest biotech by market cap
Amgen leads the 24 biotech ranked by market value, at TRY 12.49T, ahead of Gilead Sciences (TRY 10.65T) and Moderna (TRY 4.22T). Figures as of 18 Nov 2026, 12:44 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenTRY 12.49T
- Median
- TRY 523.1B
- Combined market value
- TRY 42.82T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Market cap ↓ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | TRY 12.49T | TRY 23,096.60 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | TRY 10.65T | TRY 8,587.40 | 1.60% up | 33% up | ||
| 3 | ModernaMRNA · Health Care | TRY 4.22T | TRY 10,430.37 | 3.93% down | 755% up | ||
| 4 | argenxARGX · Health Care | TRY 3.01T | TRY 47,790.04 | 0.36% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | TRY 1.87T | TRY 12,649.09 | 0.34% down | 49% up | ||
| 6 | Revolution MedicinesRVMD · Health Care | TRY 1.77T | TRY 8,205.59 | 2.50% down | 131% up | ||
| 7 | BioNTechBNTX · Health Care | TRY 1.06T | TRY 4,280.08 | 0.47% down | 16% down | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | TRY 847B | TRY 8,368.50 | 0.37% up | 20% up | ||
| 9 | ExelixisEXEL · Health Care | TRY 843B | TRY 3,454.93 | 2.09% up | 63% up | ||
| 10 | Bio-TechneTECH · Health Care | TRY 575.5B | TRY 3,663.24 | 0.22% down | 26% up | ||
| 11 | Halozyme TherapeuticsHALO · Health Care | TRY 551.9B | TRY 4,840.44 | 0.55% down | 37% up | ||
| 12 | Kymera TherapeuticsKYMR · Health Care | TRY 523.2B | TRY 6,129.10 | 3.44% down | 87% up | ||
| 13 | RepligenRGEN · Health Care | TRY 522.9B | TRY 8,179.87 | 0.37% down | 5% up | ||
| 14 | QiagenQGEN · Health Care | TRY 518.1B | TRY 2,509.24 | 0.12% down | 12% up | ||
| 15 | VaxcytePCVX · Health Care | TRY 474.3B | TRY 2,995.96 | 3.59% down | 22% up | ||
| 16 | Krystal BiotechKRYS · Health Care | TRY 446.2B | TRY 15,057.96 | 0.22% up | 46% up | ||
| 17 | Twist BioscienceTWST · Health Care | TRY 374.5B | TRY 5,648.94 | 6.63% up | 340% up | ||
| 18 | CG OncologyCGON · Health Care | TRY 355.6B | TRY 3,981.49 | 6.89% down | 85% up | ||
| 19 | ImmunovantIMVT · Health Care | TRY 346.6B | TRY 1,675.01 | 0.21% down | 43% up | ||
| 20 | ImmunityBioIBRX · Health Care | TRY 335.9B | TRY 315.74 | 4.68% up | 193% up | ||
| 21 | Kodiak SciencesKOD · Health Care | TRY 319.3B | TRY 4,882.30 | 3.90% down | 396% up | ||
| 22 | Scholar Rock HoldingSRRK · Health Care | TRY 277.4B | TRY 2,273.70 | 1.21% up | 14% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | TRY 232.6B | TRY 1,436.95 | 2.22% up | 88% up | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | TRY 196.4B | TRY 2,025.04 | 0.54% down | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 50.4370 TRY).
Questions and answers
Which biotech rank first by market value?
Amgen (TRY 12.49T), Gilead Sciences (TRY 10.65T) and Moderna (TRY 4.22T) are the top three of the 24 biotech ranked by market value as of 18 Nov 2026, 12:44 UTC.
How many biotech are in this ranking?
24 are ranked by market value.
What are these biotech worth together?
The 24 biotech ranked by market value have a combined market value of TRY 42.82T as of 18 Nov 2026, 12:44 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by market cap”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech
Underlying data: Yahoo Finance; SEC EDGAR.